Copyright
©The Author(s) 2020.
World J Hepatol. Aug 27, 2020; 12(8): 493-505
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.493
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.493
Ref. | Type of study; country | Number of patients | Treatment | Effects on NAFLD |
Kahal et al[45], 2014 | Prospective; United Kingdom | 36 | Liraglutide 0.9 mg/d for 6 mo | Serum procollagen type 3 amino-terminal peptide levels, a marker of hepatic fibrosis, decreased in women with PCOS |
Eguchi et al[46], 2014 | Prospective; Japan | 26 | Liraglutide 0.9 mg/d for 24-96 wk | ALT activity decreased. NASH decreased in 6/10 patients who underwent repeat biopsy at 96 wk |
Suzuki et al[47], 2013 | Retrospective; Japan | 46 | Liraglutide 0.9 mg/d for 6 mo | Liver to kidney attenuation ratio in CT (an index of hepatic steatosis) increased |
Ohki et al[48], 2012 | Retrospective; Japan | 82 | Liraglutide 0.9 mg/d for 340 d or sitagliptin 50-100 mg/d for 250 d or pioglitazone 15 mg/d for 1200 d | ALT activity was reduced with all agents. Liraglutide and pioglitazone but not sitagliptin reduced the APRI score |
Jendle et al[49], 2009 | Randomized controlled; multicenter | 160 | Liraglutide 0.6, 1.2 or 1.8 mg/d or glimepiride 4 mg/d or placebo for 26 wk | Liver to spleen attenuation ratio in CT (a marker of hepatic steatosis) increased in patients treated with liraglutide 1.8 mg/d and did not change in those treated with lower doses of liraglutide or glimepiride. ALT activity showed comparable decreases with both agents |
Khoo et al[50], 2009 | Randomized controlled; Singapore | 30 | Liraglutide 3 mg/d for 16 wk or lifestyle modification | Liraglutide was effective for decreasing weight, hepatic steatosis and hepatocellular apoptosis, but benefits were not sustained after discontinuation, in contrast with lifestyle modification |
Feng et al[51], 2017 | Randomized controlled; China | 87 | Liraglutide, metformin, or gliclazide for 24 wk | Liraglutide has better results in improving liver function, reductions in intrahepatic fat content and HbA1c level, and weight loss than metformin and gliclazide |
Bouchi et al[52], 2017 | Randomized controlled; Japan | 19 | Liraglutide 0.9 mg/d plus insulin or insulin alone for 14 wk | Liraglutide reduces visceral fat, hepatic fat accumulation, albuminuria and micro-inflammation and improves QOL |
Petit et al[53], 2017 | Prospective; France | 68 | Liraglutide 1.2 mg/d for 6 mo | Liraglutide significantly reduced liver fat content |
Armstrong et al[54], 2016 | Double-blind, randomized, controlled; multicenter United Kingdom | 52 | Liraglutide 1.8 mg/d or placebo for 48 wk | Liraglutide led to histological resolution of NASH |
Smits et al[55], 2016 | Randomized placebo-controlled; Holland | 52 | Liraglutide 1.8 mg/d, sitagliptin 100 mg/d or placebo | Liraglutide or sitagliptin treatment does not reduce hepatic steatosis or fibrosis |
Zhang et al[56], 2016 | Randomized controlled; China | 835 | Liraglutide 1.2 mg/d or metformin 500 mg/3 times per day | Liraglutide improves the blood glucose and lipid levels as well as liver function |
Tian et al[57], 2018 | Randomized controlled; China | 127 | Liraglutide 0.6-1.2 mg/d or metformin 1000-1500 mg/d for 12 wk | Liraglutide decreases ALT levels and is more effective than metformin at alleviating liver inflammation and improving liver function |
Cuthbertson et al[33], 2012 | Prospective; United Kingdom | 25 | Exenatide 10 mg twice daily or liraglutide 1.2 mg/d | Both liraglutide and exenatide reduce body weight, HbA1c and intrahepatic lipid accumulation |
Newsome et al[58], 2019 | Retrospective (data from 2 trials); United Kingdom | 957 (trial 1) and 3297 (trial 2) | Semaglutide 0.05, 0.1, 0.2, 0.3 or 0.4 mg/d for 52 wk (trial 1) and semaglutide 0.5 or 1.0 mg/wk for 104 wk (trial 2) | Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes |
- Citation: Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World J Hepatol 2020; 12(8): 493-505
- URL: https://www.wjgnet.com/1948-5182/full/v12/i8/493.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i8.493